Board Meeting No 5 2019
Board Meeting No 5. June 25th 2019
Notice and Protocol Annual Meeting 2019
June 25th 2019 Notice of Annual Meeting June 25th 2019. The Annual Meeting 2019 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
Annual Report 2018
Regenics post a positive 2018 result of 1.72 mill NOK. 
3D-bioprinting - ERA-NET BlueBio Joint Transnational Call 2019
BlueBio Joint Transnational Call 2019
Board Meeting No 4 2019
Board Meeting No 4 2019, May 8th 2019
Paragon Nordic AB - Collaboration
Paragon Nordic AB - Collaboration
Patent annuities paid 2019
Regenics patents due for annuity/fee payments in May 2019 have been paid and continued by our patent legal consultant.
Filing of additional Hong Kong patent application
The Patents registry of the Hong Kong Intellectual Property Department has verified receipt of Hong Kong Patent Application No. 16104205.5 from Regenics on January 25th 2019. The Hong Kong patent...
Filing of new US provisional patent application
Filing of new US provisional patent application
Board Meeting No 2 2019
March 5th 2019. 
Regenics Board Meeting No 1 2019
January 23rd 2019.  
Protocol Extraordinary Annual Meeting January 23rd 2019
January 23rd 2019 Protocoll of Extraordinary Annual Meeting January 23rd 2019. The Extraordinary Annual Meeting 2019 took place in the Companys office, Karvesvingen. 2, Oslo
New EPO Patent granted 2018
New EPO patent
Eqology AS launch Collagen Booster Serum
 An important commercial milestone has been reached for Regenics December 10th with the launch of the ground breaking EQ Collagen Boosting Serum from the Norwegian Direct Selling Company Eqology AS.  
Protocol from Extraordinary Annual Meeting September 26th 2018
September 26th 2018 Protocol of Extraordinary Annual Meeting September 26th 2018. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
Notification of grant:Divisional EPO patent
Notification of grant: Divisional EPO patent

<<  <   Page 2 of 8   >  >>


June 17-19th 2019

The Smart Patient. Regenics (CEO H.Lund co-chair)

Program 2019

December 15th 2018

DnB Healtcare Conference 2018


October 5-6th 2018

Wound Healing and Skin Diseaes, Los Angeles (CEO H.Lund keynote invitation)

June 19th – 20th 2018

Conference Biotech-Medtech-Expo, Stavanger (CEO H.Lund co-chair)

Program (tbd)


June 5-6th 2017

Investor Conference Biotech-Medtech, Stavanger (CEO co-chair)

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare Regenics presentation

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics presented abstract.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics presented abstract

Abstract 7th ETRS-WHS meeting

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.